erythrosine has been researched along with mesalamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aksenov, MY; Aksenova, MV; Butterfield, DA; Carney, JM; Cole Harper, P; DeAtley, SM; Hadley, R; Harris, B | 1 |
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
2 other study(ies) available for erythrosine and mesalamine
| Article | Year |
|---|---|
Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Chromans; Cyclic N-Oxides; Dose-Response Relationship, Drug; Doxorubicin; Fluoresceins; Heart; Mesalamine; Myocardium; Nitrogen Oxides; Oxidative Stress; Rats; Reactive Oxygen Species | 1999 |
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |